In a report released today, Joanne Wuensch from Citi reiterated a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report). The ...

GE HealthCare has delivered the initial subject doses of Flyrcado (flurpiridaz F 18) injection, for coronary artery disease ...

GE HealthCare (GEHC) has delivered the first patient doses of Flyrcado or flurpiridaz F 18 njection, a first-of-its-kind unit dose positron ...

Patients undergo first doses of GE HealthCare's PET radiotracer Flyrcado (flurpiridaz F 18) injection at early adopter sites ...

Market Growth Is Driven by Technological Innovations and An Increasing Incidence of Chronic Diseases.Pune, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Global Positron Emission Tomography Market Size & Growth ...

Advance Auto (NYSE:AAP), and Freshworks (NASDAQ:FRSH) to its portfolio in Q4 2024, while exiting Smartsheet (SMAR), CBRE (NYSE:CBRE), and Monday.com (NASDAQ:MNDY), it disclosed in its 13F filing on ...

Revenue: $5.3 billion for Q4 2024, with organic growth of 2%. Service Revenue Growth: 6% increase on a reported basis in Q4 2024. Product Revenue Growth: 1% increase on a reported basis in Q4 2024.

The company announced the planned launch of Flyrcado, a radiopharmaceutical product for myocardial perfusion imaging, in April 2025. It is expected to generate $30 million in revenue for 2025 and ...

ARLINGTON HEIGHTS, Ill. - GE HealthCare (NASDAQ: NASDAQ:GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, a new... ByInvesting.com • Sep ...

The state’s life sciences industry honored its own last Thursday night at BioNJ’s annual Dinner Meeting & Innovation Celebration. Held at the Hilton East Brunswick, the gala represented a who’s who of ...

ARLINGTON HEIGHTS, Ill. - GE HealthCare (NASDAQ: NASDAQ:GEHC) has received U.S. Food and Drug Administration (FDA) approval for Flyrcado™ (flurpiridaz F 18) injection, a new... ByInvesting.com ...